Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hyman

Showing results (371-380 of 401) with videos related to

Pageof 41
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Nature|July 12, 2019
Tumour lineage shapes BRCA-mediated phenotypesPhilip Jonsson, Chaitanya Bandlamudi, Michael L Cheng, et al.
Cancer Discovery|December 17, 2017
Accelerating Discovery of Functional Mutant Alleles in CancerMatthew T Chang, Tripti Shrestha Bhattarai, Alison M Schram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2017
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical PhenotypeMaeve A Lowery, Emmet J Jordan, Olca Basturk, et al.
Nature|December 12, 2019
Author Correction: Tumour lineage shapes BRCA-mediated phenotypesPhilip Jonsson, Chaitanya Bandlamudi, Michael L Cheng, et al.
The New England Journal of Medicine|February 23, 2022
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase InhibitorsEric Wang, Xiaoli Mi, Meghan C Thompson, et al.
Journal of the National Cancer Institute|March 6, 2018
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic NeoplasmsMaeve A Lowery, Winston Wong, Emmet J Jordan, et al.
Cancer Discovery|October 26, 2018
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase InhibitionJames J Harding, Maeve A Lowery, Alan H Shih, et al.
Cancer Discovery|June 5, 2017
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid TumorsAlexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, et al.
Nature Medicine|November 27, 2019
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasmsBenjamin H Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, et al.
Pageof 41

Showing results (371-380 of 401) with videos related to

Sort By:
Pageof 41
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Nature|July 12, 2019
Tumour lineage shapes BRCA-mediated phenotypesPhilip Jonsson, Chaitanya Bandlamudi, Michael L Cheng, et al.
Cancer Discovery|December 17, 2017
Accelerating Discovery of Functional Mutant Alleles in CancerMatthew T Chang, Tripti Shrestha Bhattarai, Alison M Schram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2017
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical PhenotypeMaeve A Lowery, Emmet J Jordan, Olca Basturk, et al.
Nature|December 12, 2019
Author Correction: Tumour lineage shapes BRCA-mediated phenotypesPhilip Jonsson, Chaitanya Bandlamudi, Michael L Cheng, et al.
The New England Journal of Medicine|February 23, 2022
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase InhibitorsEric Wang, Xiaoli Mi, Meghan C Thompson, et al.
Journal of the National Cancer Institute|March 6, 2018
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic NeoplasmsMaeve A Lowery, Winston Wong, Emmet J Jordan, et al.
Cancer Discovery|October 26, 2018
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase InhibitionJames J Harding, Maeve A Lowery, Alan H Shih, et al.
Cancer Discovery|June 5, 2017
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid TumorsAlexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, et al.
Nature Medicine|November 27, 2019
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasmsBenjamin H Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, et al.
Pageof 41